|
|
★
小木虫(金币+0.5):给个红包，谢谢回帖交流
这个品种要慎重考虑，为什么，我来说说，希望楼主不要介意，也希望对这个项目感兴趣的人慎重考虑。市场、疗效、不良反应什么的感兴趣的人可以自己去查，但是，WHO对该药有评论：
United Nations – New York, 2003
Pharmaceuticals
Eighth Issue
or not Approved by Governments
Banned, Withdrawn, Severely Restricted
Whose Consumption and/or Sale Have Been
Consolidated List of Products
Product Name Cinepazide
C.A.S. number 23887-46-9
Scientific and common names, and synonyms
1-[(1-PYRROLIDINYLCARBONYL)METHYL]-4-(3,4,5-TRIMETHOXYCINNAMOYL) PIPERAZINE
EGY 1988 ，Registration of products containing cinepazide was refused, having regard to international reports of blood dyscrasias associated with their use.（1988年在埃及注册申请因药物不了反应被拒绝。）
ESP 1988， In agreement with the Ministry of Health, products containing cinepazide have been withdrawn by the manufacturers.（1988年应西班牙卫生部门要求生产厂商退市。）
WHO Comment : Cinepazide, a vasodilating agent, was first introduced into medicine in 1974. It is used in the treatment of peripheral and cerebral vascular disorders. Following reports of blood dyscrasias, including agranulocytosis and thrombocytopenia, associated with the use of the drug, the Spanish Committee on Drug Surveillance has recommended its withdrawal. In other countries, the approved product information of preparations containing cinepazide has been amended to include a relevant warning on these adverse effects.（WHO评论：桂哌齐特，1974年上市，用于治疗外周血管及大脑血管病症，用药过程中出现粒性白细胞减少、血小板减少，西班牙药品监督委员会将其撤市，在其他核准上市的地区，与药物有关主要不良反应导致的后果均被要求对病人进行赔偿。）
赛诺菲-安万特原创，法国（1974）、瑞士（1975）、意大利（1978）、南韩（1980）、印尼（1981）和巴西（1980）上市，用于治疗下肢动脉炎、伯格氏病（血栓闭塞性脉管炎）、脉管炎、急性甲磺双氢麦角胺中毒、雷诺氏现象、糖尿病动脉病和循环功能不全；作为Vasolande在西班牙的Prem（1980）上市；以马来酸桂哌齐特在阿根廷（1983）上市；作为Brendil在日本的Daiichi药业(现在的Daiichi Sankyo) (1981) 上市；作为Cinepadil在香港上市。在91年11月28日被ML更新。
国家医保目录药物，新药转正标准第59册，BP、EP、USP等均未收载，只收载于马氏大药典，FDA均为查到相关信息。 |
|
回复此楼